The regimen was BGB324 datasheet also modified to avoid potential drug interactions with concomitant medications. Prophylaxis
was given for 28 days but was stopped earlier if the source subject tested HIV negative or the exposed patient was found to be positive at baseline testing. At the first visit, demographic data were collected from exposed patients as well as information on the nature of exposure and risk factors for HIV infection for themselves and for source subjects. When nPEP was prescribed, a second visit was planned 2 weeks later to ascertain drug adherence and tolerance. Risk-reduction counselling was provided on each visit. Complete blood count and renal and liver function tests were assessed at baseline and at week 2. For all participants, antibody and p24 antigen HIV testing was offered at baseline and was repeated at 3 and 6 months. From 1998 to 2006, a third-generation assay (Roche Cobas Core anti-HIV 1+2+O EIA; Roche Diagnostics GmbH, Mannheim, Germany) combined with a p24 antigen assay (Roche Cobas HIV Ag) was performed, whereas from 2006 onwards, a fourth-generation assay (Cobas HIV
Combi®; Roche) was used. From 2006 onwards, the 6-month test selleckchem was no longer performed following an update of our national guidelines . When the source of exposure was found to be HIV negative, the decision to conduct follow-up HIV testing was left to the physician’s discretion when there was 4-Aminobutyrate aminotransferase a suspicion that the source might be in the preseroconversion window period. A descriptive analysis of demographic data, the nature of exposure and risk factors for HIV infection was performed. Exposed subjects were categorized into risk groups. The likelihood of being able to contact and test the source of exposure was determined in each risk category of exposed patients by univariate analysis. We used Student’s t-test when continuous variables
were normally distributed and the Mann–Whitney U-test for skewed distributions. Categorical variables were analysed using Fisher’s exact test. Data were analysed using stata 10.0 (Stata Corporation, College Station, TX, USA). Between 1998 and 2007, 1233 consultations for potential HIV exposure were recorded. A marked and steady increase was noted in the number of consultations per year, rising from 20 in 1998 to 196 in 2007 (+850%). Of these, 27 occurred in the healthcare setting and were therefore excluded. One hundred and thirty-eight consultations were also excluded from analysis because of missing data (90 cases), absence of exposure (34) and refusal of medical care by the subject (14). Among the remaining 1068, 158 exposures did not meet indications for nPEP prescription (Fig. 1). Overall, 910 events involving a total of 867 persons were included in the final analysis.